PLK1 and myelodysplastic syndrome: These three studies were all prematurely discontinued when the clinical development of volasertib was discontinued, following a strategic decision by the sponsor; however, they provide useful insights into the safety profile and preliminary clinical activity of a PLK inhibitor as a treatment for MDS/CMML.